While BRAF and MEK inhibition is a common tactic for treating melanoma, ERK-specific targeting has been rare despite its placement downstream of both BRAF and MEK, which has a more direct effect on the genetic and proliferative effects of the MAPK signaling pathway. Here, MAP2K7 is linked to melanoma.